General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT03111446
Collaborator
(none)
60
1
2
8.6
7

Study Details

Study Description

Brief Summary

Anesthesia for caesarian section in patients with HELLP syndrome is a challenge. Measures should be taken during caesarian delivery to guard against the maternal and fetal complications associated with HELLP syndrome.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Spinal Anesthesia
  • Procedure: General Anesthesia
N/A

Detailed Description

The choice of anesthesia for caesarian section in parturient with HELLP syndrome is a debate. The low platelet count, associated with HELLP syndrome, has often favored the choice of general anesthesia for the caesarian delivery of these parturient. However, general anesthesia in such cases; is not a risk-free approach. General anesthesia is associated with increased risk of difficult airways, stress response to intubation and aspiration. It is also thought to have an effect on the fetus with the potential placental transfer of inhalational anesthetics prior to delivery.

Regional anesthesia is widely regarded as a means of providing analgesia for cesarean section.it also avoids the above-mentioned risks associated with general anesthesia. Regional anesthesia for caesarian section in patients with HELLP syndrome has been used by some researchers in many centers with encouraging results.

The lowest platelet count at which one can safely administer neuraxial anesthesia for labour and delivery is controversial. Published studies are few and sample sizes small.

Criteria developed at the University of Mississippi, as of 2006: "For a patient to merit a diagnosis of HELLP syndrome, class 1 requires severe thrombocytopenia (platelets ≤50,000/μl), evidence of hepatic dysfunction (AST and/or ALT ≥70 IU/l), and evidence suggestive of hemolysis (total serum LDH ≥600 IU/l); class 2 requires similar criteria except thrombocytopenia is moderate (>50,000 to ≤100,000/μl); and class 3 includes patients with mild thrombocytopenia (platelets >100,000 but ≤150,000/μl), mild hepatic dysfunction (AST and/or ALT ≥40 IU/l), and hemolysis (total serum LDH ≥600 IU/L).

The researchers chose to investigate class 2 HELLP syndrome as class 3 proved to be safe with regional anesthesia while class 1 seemed to be high risk and un-ethical to do spinal anesthesia with very low platelets count with lack of any evidence to its safety.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome
Actual Study Start Date :
Apr 15, 2017
Actual Primary Completion Date :
Dec 1, 2017
Actual Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Spinal Anesthesia

Spinal anesthesia will be used to anesthetize patients in this group for caesarian section

Procedure: Spinal Anesthesia
Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.

Active Comparator: General Anesthesia

Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section

Procedure: General Anesthesia
Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.

Outcome Measures

Primary Outcome Measures

  1. The incidence of perioperative mortality in both groups. [up to one week postoperative]

    Maternal

Secondary Outcome Measures

  1. occurence bradycardia [up to 24 hours postoperative]

    heart rate less than 50 beat/min

  2. occurrence of tachycardia [up to 24 hours postoperative]

    heart rate more than 120 beats/min

  3. occurrence of hypotension [up to 24 hours postoperative]

    mean arterial blood pressure < 40% of the baseline

  4. occurrence of hypertension [up to 24 hours postoperative]

    mean arterial blood pressure > 40% of the baseline

  5. incidence of cerebral hemorrhage [up to one week postoperative]

    detected by CT in patients with neurological deficits

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Patients with class (II) (12) HELLP syndrome scheduled for elective caesarian section:

Diagnosis of HELLP syndrome was based on the clinical diagnosis of preeclampsia and the following laboratory abnormalities (13):

  1. Hemolysis: characteristic peripheral blood smear, serum lactic dehydrogenase (LDH) ≥ 600 U/ l, total bilirubin ≥ 1.2 mg /dl, decreased hemoglobin and hematocrit.

  2. Elevated liver enzymes, defined as aspartate aminotransferase (AST). ≥ 70 U/ l, alanin aminotransferase (ALT) ≥ 50 U/ l and lactate dehydrogenase (LDH) ≥ 600 U/ l.

  3. Low platelet count: class 2 HELLP having a platelet nadir between > 50000 and 100000 mm-3.

Exclusion Criteria:
  1. Emergency cases

  2. Placenta praevia

  3. Cardiovascular or cerebrovascular disease.

  4. Morbid obesity with a BMI ≥40

  5. Gestational age <36 or >41 weeks

  6. Platelet counts less than 50000 mm-3; class 1 HELLP and class 3 HELLP having platelet count more than 100 000 mm-3

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assiut university hospital, Faculty of medicine Assiut Egypt 71516

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amr Talaat Mostafa, Dr., Assiut University
ClinicalTrials.gov Identifier:
NCT03111446
Other Study ID Numbers:
  • SpinalHELLP
First Posted:
Apr 12, 2017
Last Update Posted:
May 18, 2018
Last Verified:
Apr 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2018